Genmab A/S (LTS:0MGB)
kr 1839.5 -9.25 (-0.5%) Market Cap: 117.16 Bil Enterprise Value: 88.58 Bil PE Ratio: 22.03 PB Ratio: 3.66 GF Score: 84/100

Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 03:45PM GMT
Release Date Price: kr2346 (+3.67%)
Matthew Kelsey Harrison;Jan G. J. van de Winkel;S<
Morgan Stanley, Research Division - Executive Director;Genmab A

Great. Good morning, everybody, again. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Genmab with me for the next session.

Just quickly before we get started, I need to read a disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales representative.

So very pleased to have Jan van de Winkel, who's the CEO of Genmab; and Anthony Pagano, who is the CFO with me today.

And Jan, I'm going to turn it over to you for some opening comments, and then we'll get into Q&A.

- /

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot